Alumis reports Phase 2b SLE trial results for envudeucitinib

• Alumis reported Phase 2b LUMUS results for envudeucitinib in moderate-to-severe systemic lupus erythematosus.
• The overall study population did not meet the primary BICLA endpoint or key secondary endpoints.
• A high interferon gene signature subgroup showed responses across measured clinical endpoints.

Alumis (NASDAQ:ALMS) reported Phase 2b LUMUS trial results for oral TYK2 inhibitor envudeucitinib in moderate-to-severe systemic lupus erythematosus, with the overall study population not meeting the primary endpoint.

The trial did not achieve the primary BICLA endpoint or key secondary endpoints including CLASI-50, SRI-4 and LLDAS, while a prespecified subgroup with high interferon gene signature showed responses across the measured outcomes.

Alumis said pharmacodynamic data showed dose-dependent interferon pathway target engagement, with maximum suppression observed at 40 mg twice daily, and reported that envudeucitinib was generally well tolerated with no new safety signals.

The company plans to discuss Phase 3 SLE development options with regulators, while remaining on track to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.

Alumis is developing oral therapies targeting immune pathways for autoimmune and inflammatory diseases.

The company said it is also evaluating envudeucitinib’s potential in interferon-driven conditions including cutaneous lupus and Sjögren’s disease.